卡耐基梅隆大学生物技术创新计算项目招生介绍

[size=13.333333969116211px]讲座时间： 1月18日周五下午5:00-6:00pm[size=13.333333969116211px]讲座地点： SAV 131

[size=13.333333969116211px][size=13.333333969116211px]

Target audience: students applying for graduate schools.

This seminar introduces the new MSBIC program at Carnegie Mellon. The Master of Science in Biotechnology Innovation and Computation Degree (MSBIC) at the School of Computer Science focuses on solving real life problems using big data, machine learning, information retrieval, and language technologies. Working with computer scientists and industry leaders, students will immerse themselves in cutting edge computer science and bioinformatics topics, in a simulated startup environment, working on their big ideas that can have a real impact. Students have opportunity to learn from experts in multiple disciplines and C-level executives from biotech industries on how to find ideas, how to turn ideas into products, and the essence of running a successful startup or a venture within an established company. For example, applying the OAQA technology that helped IBM’s Watson defeat humans in Jeopardy in the field of bioinformatics. Past and current students have job or internship offers to Apple, Microsoft, Google, Oracle, Facebook, IBM, CISCO, or started their own ventures.

If you are interested in the program, please email [email protected].

[size=13.333333969116211px]

Faculty Members and Industry Advisors (sample list):

John Vu, Program Director
	John Vu is the Director of the M.S. in Biotechnology Innovation and Computation program as well as Distinguished Career Professor in the School of Computer Science. John was a Chief Engineer and Technical Fellow (retired) at The Boeing Company where he led several successful programs including the integration of computer design systems for the 777, IT integration into Lean Manufacturing and various company wide software improvement initiatives. John has over 35 years of experience in software and systems development and has managed several large-scale integration programs in which the final products required the integration of in-house components with commercial off-the shelf products and outsourced suppliers. John has participated in the development of several Capability Maturity Models (CMMIs) at the Software Engineering Institute (SEI) and authored the software e-commerce model and the procurement model. He was a member of the IEEE Software Industry Advisory Board and has written many books and articles on software project and program management. John received master's degrees from Carnegie Mellon University and the University of Nevada in addition to undergraduate degrees from Ohio University and Seattle Pacific University. He is also a lecturer at Carnegie Mellon Silicon Valley, Seattle University, the Korean Advanced Institute of Science and Technology and Tsinghua University.
Eric Nyberg, Co-Director
	Eric Nyberg is a Professor in the Language Technologies Institute. He is the co-Director for the M.S. Program in Biotechnology, Innovation, and Computation as well as the MSIT Program in Very Large Information Systems. Dr. Nyberg has made significant research contributions to the fields of automatic text translation, information retrieval and automatic question answering. His research has been funded by global corporations (including IBM, Caterpillar, Daimler-Benz, Hewlett-Packard, Hitachi and Denso), and a variety of U.S. government agencies. Dr. Nyberg received his Ph.D. from Carnegie Mellon University and his BA from Boston University. In 2012, Dr. Nyberg received the Allen Newell Award for Research Excellence for his scientific contributions to the field of question answering and his work on IBM's Watson project.
Jaime Carbonell
	Jaime Carbonell is the Allen Newell Professor in the School of Computer Science. He is the Director of the Language Technologies Institute. Overall, he has published over 250 articles and books. His research includes text and data mining, machine translation, reasoning under uncertainty, and computational proteomics where he investigates machine learning and language technologies to predict proteomic 3D structure (a.k.a. "the folding problem") and function. Dr. Carbonell has served on various advisory committees including the NIH Human Genome Advisory Committee and the National German AI Lab (DFKI) Scientific Advisory Board. He has also served as an advisor for numerous technology startups and companies, and has consulted to large financial institutions such as Citigroup. He received his MS and Ph.D. from Yale University and his BS in Physics from MIT.
Mark Ahn
	Mark J. Ahn, Ph.D. is President & Chief Executive Officer, and Director of Galena Biopharma (Nasdaq: GALE) and Professor (adjunct), Biosciences, Creighton University. Prior to Galena , Dr. Ahn was Principal at Pukana Partners, Ltd. that provides strategic consulting to life science companies; and Associate Professor, Global Management at Atkinson Graduate School of Management, Willamette University. He previously served as Chair, Science & Technology Management, Victoria University at Wellington, New Zealand. Dr. Ahn was also founder, President, and Chief Executive Officer of Hana Biosciences. Prior to Hana, he served as Vice President, Hematology and corporate officer at Genentech, Inc., as well as held positions of increasing responsibility at Amgen and Bristol-Myers Squibb Company; and served in the US Army. Dr. Ahn also serves on public and venture capital-backed Board of Directors for Access Pharmaceuticals, Mesynthes and Scribes STAT. Dr. Ahn is the author of over 50 peer reviewed journal articles and books including Making the Case for Biotechnology (Logos Press). Dr. Ahn received a BA and MBA from Chaminade University; and MA from Victoria University. He was a graduate fellow in Economics at Essex University, and obtained a Ph.D. from the University of South Australia. Dr. Ahn is a Henry Crown Fellow at the Aspen Institute.
Richard Chin
	Richard Chin is currently the CEO of One World Health. He has overseen over 40 Investigational New Drug (IND) Applications for new molecular entities and new indications, as well as eight New Drug Applications (NDAs)/Biologic License Applications (BLAs). Dr. Chin joined One World Health from OXiGENE, where he served as President and CEO. Previously, Dr. Chin served as Senior VP and Head of Global Development for Elan Corporation, where he had worldwide responsibility for Clinical Development, Regulatory, Biostatistics, CMC, QA/Compliance, Safety and Medical Affairs. Dr. Chin has also held various clinical and scientific roles for Genentech, Inc. including Head of Clinical Research for the Biotherapeutics Unit, overseeing approximately half of the drugs at Genentech, and began his career at Procter and Gamble Pharmaceuticals, where he served as Associate Medical Director. He received a B.A. in Biology from Harvard University and the equivalent of a J.D. with honors from Oxford University in England under a Rhodes scholarship. Dr. Chin received his MD from Harvard Medical School.